Partnering and Business Opportunities:
If interested in any of these projects, please contact Jeewon Kim, Business Development Manager of SPARK
|Anti-infective, Otolaryngology (ENT)||Small Molecule||sk13180||
Nanoparticle as Targeted Anti-biofilm Adjunctive Therapy to Treat Pseudomonas aeruginosa Infection in Chronic Suppurative Otitis Media: Gold nanocluster that eradicates persister cells in bacterial biofilms. Confirmed complete eradication across extensively drug resistant ESKAPE organisms, gram +ve and -ve and clinical isolates. Gold nanocluster works by a novel mechanism in both aerobic and anaerobic conditions by uniquely inducing apoptosis in low metabolic bateria for eradication; Looking for funding to take the product through IND enabling studies and into first in human studies.
Direct Mitochondrial Augmentation Therapy for heart Failure, mitochondrial disease and skeletal muscle frailty/aging using iPSC-derived Extracellular Vesicles. Interested in funding, partnership and licensing.
Company name: Azora Therapeutics. It is a clinical-stage biotech company developing potential first-in-class/best-in-class aryl hydrocarbon receptor (AhR) agonists for moderate-severe ulcerative colitis (UC), mild-moderate hidradenitis suppurativa (HS), and moderate-severe nail psoriasis. Azora is developing a colon- targeted oral for UC (AT-177) and a topical for skin inflammatory diseases (AT-193). Azora has two ongoing Phase 1b studies in HS and nail psoriasis in Australia which are expected to be completed in 2022/2023. Azora also has an open-IND for their UC program and plans to initiate a clinical study in 2022. Azora is actively seeking strategic partnerships or to raise additional financing in 2022/2023.
|Gene Therapy||Gene/Cell Therapy||sk10134||
Innovative platform to enhance Adeno-associated virus (AAV)-based gene therapy. Identified a host factor to improve AAV infection for all serotypes and cell types.
|Gene Therapy, Pediatrics||Gene/Cell Therapy||sk12163||
Transient telomere extension using TERT mRNA for patients with Idiopathic lung fibrosis, chronic liver disease (CLD), idiopathic pulmonary fibrosis (IPF), bone marrow failure (BMF), and skin diseases. Company Name: Rejuvenation. INTERACT meeting completed. Looking for clinical co-development partnership.
|Hematology, Immunology||Antibiotic, Gene/Cell Therapy||sk08095||
Therapeutic monoclonal antibody to treat acute graft versus host disease (GVHD) (orphan disease).
Clinical Development and Commercialization of [18F]DASA-23, an Imaging Strategy for the Improved Management of Glioblastoma. Used to assess the ability of [18F]DASA-23 PET to assess therapeutic response or failure acutely (within weeks of initiation of therapy) in patients with glioblastoma. In clinical trials.
SM to prevent progression of fibrotic autoimmune disease. Phase I complete and animal data available (Orphan indication with 7 years exclusivity). Extensive safety and tolerability and intellectual property secured.
Small molecule inducer of beta cell regeneration for treatment of type 2 diabetes. Lead compound optimization on-going.
Novel targets for induction of brown fat from white fat to treat obesity. Preparing high-throughput screening to identify small molecule inhibitors.
Company name: Aza Technology. FDA Advantaged: FDA has granted Aza breakthrough status for its innovative device, thanks to its excellent performance in clinical studies and urgent unmet clinical need. Aza Technology is poised to deliver a point-of-care device targeting diagnosis and management of hyperammonemia, which is responsible for a host of neurotoxic effects seen in Urea Cycle Disorder (UCD) and organic acidemia (OA) patients. Hyperammonemia is also a root cause of hepatic encephalopathy, a serious condition that occurs secondary to alcoholic and non-alcoholic cirrhosis (NASH), resulting in over $2 billion in hospitalizations in the US alone.
Novel antibodies plus companion imaging agent to detect and treat toxic inflammatory age-related diseases. Company Name: Willow Therapeutics
Developing small molecule, tissue-selective agonists for the treatment of disorders associated with mitochondrial dysfunction, including neurodegenerative disorders (ie. Alzheimer’s and Parkinson’s Disease) and retinal degenerative disorders (ie, Age-related macular degeneration). Company Name: Evvia
Identified the cause of a mitophagy defect present in Parkinson’s disease patients, consisting of both genetic and sporadic patients. Using this initial discovery, built and validated a mitophagy drug discovery platform, which includes a peripheral biomarker. Company Name: AcureX
|Oncology||Diagnostic, Small Molecule||sk14205||
Company name: MEDIC Life Sciences. A young genomics biotech startup based in Mountain View, CA, developing novel oncology therapeutics for solid tumors. We are harnessing our unique 3D-tumor based CRISPR functional genomics platform (published in Nature, 2020) to identify prognostic and effective first-in-class drug targets for various solid tumors.
The team has developed a screening platform for the HAT1 enzyme, which is a critical regulator of how cells synthesize chromatin to support proliferation. This led to the identification of multiple small molecules with HAT1 inhibitory properties, including demonstration of anti-tumor activity in mice.
Modulation of tissue macrophages by inhibition of thrombin cleavage of osteopontin (OPN) enhances host-anti-tumor immune response and up-regulates tissue repair and reduces fibrotic reactions. The team has identified a therapeutic molecule that prevents thrombin cleavage of OPN and suppresses murine melanoma growth and metastasis.
|Ophthalmology||Gene/Cell Therapy, Small Molecule||sk15221||
First-in-human Neuroprotection Therapies for Glaucoma and other Optic Neuropathies